The Outcome of Autologous Stem Cell Transplantation in Adolescent and Young Adult Patients with Multiple Myeloma
Objectives: Multiple myeloma (MM) is a disease of the elderly and peaks at 60-to-70 years of age. The disease is rarely observed in young age groups. The incidence of MM is 2% among the patients under 40 years of age. Methods: In this retrospective study, we analyzed the results of MM patients in the adolescents and young adults (AYA) age group who were treated in our center between January 2010 and July 2018. Results: Of the 212 MM patients, 7% (15/212) were in the AYA age group. The median progression-free survival (PFS) was 20.3 months, and the median overall survival (OS) was 41.5 months among patients in the AYA age group. In the group of patients who were over 40 years of age, the median PFS was 19.07 months, and the median OS was 30.1 months. At the time of diagnosis, the patients in the group that was 40 years of age or older were, more frequently International Staging System (ISS) 2 and ISS 3, while patients in the AYA group were more often ISS 1. Conclusion: As the goal is to achieve longer OS, and the incidence of comorbidities in younger patients is low, augmented treatments should be considered in AYA age group MM patients.
1.Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20. [CrossRef]
2. Palumbo A, Bringhen S, Ludwig H et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118:4519–29. [CrossRef]
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–7. [CrossRef]
4. Child JA, Morgan GJ, Davies FE, et al. Highdose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–83. [CrossRef]
5. Corradini P, Cavo M, Lokhorst H, et al. for the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapsefree survival in patients with multiple myeloma. Blood 2003;102:1927–9. [CrossRef]
6. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521–6. [CrossRef]
7. Kyle RA, et al. Long-term survival in multiple myeloma. N EnglJ Med 1983;308:3146. [CrossRef]
8. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21–33. [CrossRef]
9. Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996;93:345–51. [CrossRef]
10. Blade J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med 1996;156:1463–8. [CrossRef]
11. Sagaster V, Kaufmann H, Odelga V, et al. Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System. Eur J Haematol 2007;78:227–34. [CrossRef]
12. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic cells for multiple myeloma. J Clin Oncol 2000;18:2273–81.
13. Durie BG, Harousseau JL, Miguel JS, et al. for the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73.
14. Rihn C, Cilley J, Naik P, et al. Definition Of Myeloid Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation. Haematologica 2004;89:763–4.
15. Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 1998;30:493–501. [CrossRef]
16. Yanamandra U, Saini N, Chauhan P, et al. AYA-Myeloma: RealWorld, Single-Center Experience Over Last 5 Years.J Adolesc Young Adult Oncol 2018;7:120–4. [CrossRef]
17. Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003;102:69– 77. [CrossRef]
18. Garcia-Sanz R, Gonzalez-Fraile MI, Mateo G, et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer 2004;112:884–9. [CrossRef]